Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence
Citations Over Time
Abstract
Differentiated thyroid carcinoma (DTC) is a highly prevalent endocrine malignancy. The majority of DTCs are slowly progressive and, when identified at an early stage, frequently cured with adequate surgical management and radioactive iodine-131 ablation therapy. Metastatic DTC that has become inoperable or refractory to radioactive iodine-131, however, is associated with a poor survival. Results of conventional treatment modalities have been disappointing and, therefore, new therapies are needed. As a result of the increasing knowledge of the biologic basis for thyroid cancer, therapeutic agents that target involved biologic abnormalities have been identified. Multiple clinical trials have been initiated and performed in the past years. In this article conventional and new treatment modalities in differentiated advanced thyroid cancer are described, with the focus on kinase inhibitors.
Related Papers
- → Exogenous Glucocorticoids and a High-Fat Diet Cause Severe Hyperglycemia and Hyperinsulinemia and Limit Islet Glucose Responsiveness in Young Male Sprague-Dawley Rats(2013)47 cited
- → Fasting Hyperglycemia Impairs Glucose- But Not Insulin-Mediated Suppression of Glucagon Secretion(2007)46 cited
- → The Effect of Fasting on Tissue Cyclic cAMP and Plasma Glucagon in the Obese Hyperglycemic Mouse(1975)39 cited
- → Modulation of Adipoinsular Axis in Prediabetic Zucker Diabetic Fatty Rats by Diazoxide(2004)39 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)